

# **CLINICAL STUDY REPORT**

**OSCTC-R-2021-005-01\_signed V0**

**ALPCH Co., Ltd.**

**Assessment of a primary skin  
irritation potential for the [MU:EUL  
AMPOULE ESSENCE] by human patch  
test**

**10<sup>th</sup> September 2021**

**Oracle Skin Clinical Trial Center Co., Ltd.**



## Contents

<b>Information of the study request .....</b>	<b>2</b>
<b>Authentication.....</b>	<b>3</b>
<b>Confirmation of quality assurance.....</b>	<b>4</b>
<b>Summary of the results.....</b>	<b>5</b>
1. Objective.....	7
2. Study period .....	7
3. Investigational product .....	7
4. Subjects.....	8
5. Materials to conduct the study.....	10
6. Methodology.....	10
7. Results .....	12
8. Conclusion .....	14
9. Reference.....	15
<b>Appendix 1. Inform of the subjects .....</b>	<b>16</b>
<b>Appendix 2. Ingredients of the investigational product.....</b>	<b>16</b>
<b>Appendix 3. Result data.....</b>	<b>18</b>
<b>Facilities and faculty involved in the study .....</b>	<b>19</b>
<b>Researchers CV.....</b>	<b>20</b>
<b>List of scientific publications .....</b>	<b>22</b>

## Information of the study request

<b>Study title</b>	Assessment of a primary skin irritation potential for the [MU:EUL AMPOULE ESSENCE] by human patch test
<b>Study code</b>	OSCTC-2021-005
<b>Study period</b>	From 7 <sup>th</sup> September 2021 to 9 <sup>th</sup> September 2021
<b>Report date</b>	10 <sup>th</sup> September 2021

<b>Institution</b>	<b>Name</b>	Oracle Skin Clinical Trial Center Co., Ltd.
	<b>Address</b>	4F, Hanil Building, Seolleung-ro, Gangnam-gu, Seoul, Republic of Korea
	<b>President</b>	Youngwoo Ro
	<b>Principal Investigator</b>	Youngwoo Ro / Dermatologist
	<b>Subinvestigator</b>	Yunhee Hwang
	<b>Tel.</b>	+82 10-3689-3340
	<b>e-mail</b>	oracleclinicaltrials@gmail.com

<b>Sponsor</b>	<b>Name</b>	ALPCH Co., Ltd.
	<b>Address</b>	4F, 101, Sinjeong-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea
	<b>President</b>	Seongcheol Ju
	<b>Monitor</b>	Haeyong Ro
	<b>Tel.</b>	031-693-6278
	<b>e-mail</b>	alpch@naver.com

## Authentication

- **Study title: Assessment of a primary skin irritation potential for the [MU:EUL AMPOULE ESSENCE] by human patch test.**

We had unequivocally performed this study as requested by ALPCH Co., Ltd. This study was conducted in compliance with the regulations of GCP (Good Clinical Practice) guideline, MFDS (Ministry of Food and Drug Safety), and with Standard Operation Procedure (SOP) of the Oracle Skin Clinical Trial Center Co., Ltd., we faithfully carried out the clinical study and report the results as follows:

10<sup>th</sup> September 2021

**Principal Investigator:** Oracle Skin Clinical Trial Center Co., Ltd.

**Dermatologist**

**Youngwoo Ro**

(signature)  


**Subinvestigator:** Oracle Skin Clinical Trial Center Co., Ltd.

**Department manager**

**Yunhee Hwang**

(signature)  


## Confirmation of quality assurance

- **Study title:** Assessment of a primary skin irritation potential for the [MU:EUL AMPOULE ESSENCE] by human patch test.
- **Study code:** OSCTC-2021-005

This study was conducted under the experimental protocol in consulted with the ALPCH Co., Ltd., in compliance with the regulations of GCP (Good Clinical Practice) guideline, MFDS (Ministry of Food and Drug Safety), and with standard operation procedure (SOP) of the Oracle Skin Clinical Trial Center Co., Ltd.

In addition, it is confirmed that this report was reviewed and found that it accurately reflected the results obtained during the study by a quality assurance.

Stage	Date	Check list	Result
Plan	6 <sup>th</sup> September 2021	Experimental protocol	Approval
Progress	7 <sup>th</sup> September 2021	Informed consent Form, Case Report Form	Approval
Analysis	9 <sup>th</sup> September 2021	Raw data	Approval
Report	10 <sup>th</sup> September 2021	Report	Approval

10<sup>th</sup> September 2021

**Principal Investigator:** Oracle Skin Clinical Trial Center Co., Ltd.

**Dermatologist**

**Youngwoo Ro**

(signature)

**Quality Assurance:** Oracle Skin Clinical Trial Center Co., Ltd.

**Dermatologist**

**Hyewon Shin**

(signature)

## Summary of the results

<b>Study title</b>	Assessment of a primary skin irritation potential for the [MU:EUL AMPOULE ESSENCE] by human patch test.			
<b>Study code</b>	OSCTC-2021-005			
<b>Study period</b>	From 7 <sup>th</sup> September 2021 to 9 <sup>th</sup> September 2021			
<b>Report date</b>	10 <sup>th</sup> September 2021			
<b>Institution</b>	Oracle Skin Clinical Trial Center Co., Ltd.			
<b>Objective</b>	This study was performed to evaluate the safety of the [MU:EUL AMPOULE ESSENCE] by 24-hours occlusive single patch test in human skin.			
<b>Investigational product</b>	<b>No.<sup>1)</sup></b>	<b>Product code<sup>2)</sup></b>	<b>Designation</b>	<b>Formula</b>
	01	IP-2108-034	[MU:EUL AMPOULE ESSENCE]	White cream
<sup>1)</sup> Location of the patch application				
<sup>2)</sup> Identification code of the investigational product by Oracle Skin Clinical Trial Center Co., Ltd.				
<b>Method</b>	<p>1. Subjects</p> <p>: More than 30 healthy male and female adults over the age 19 who met all inclusion and exclusion criteria.</p> <p>2. Evaluation methods</p> <p>: 24-hours occlusive single patch test, as modified by Frosch &amp; Kligman (1979), CTFA guideline (2007) and Draize methods.</p> <ul style="list-style-type: none"> <li>➤ Test area: on the back</li> <li>➤ Patch duration: 24hr occlusive patch</li> <li>➤ Reading and interpretation: To evaluate the test results, we removed the patch after 24 hours. The skin reaction was assessed at 30 min and 24 hours after removal. We calculated the mean skin reaction rate after each assessment and analyzed the irritation level.</li> </ul>			

Result	1. Subjects											
	This study was initially conducted with 31 Korean male and female adults who met all the inclusion criteria, exclusion criteria. Since 0 subject have withdrawn during the study period, total 31 subjects included this result.											
	Average age of subjects is 30.4 years old, the oldest is 42 years old and the youngest is 21 years old.											
	2. Results											
Conclusion	Dermatologist performed a visual evaluation at 30 minutes and 24 hours after removal of the patch. As a result, the [MU:EUL AMPOULE ESSENCE] was defined as "non-irritating product" with "0.00" skin irritation index score.											
	<table><tr><td>No.<sup>1)</sup></td><td>Designation</td><td>Skin irritation index</td><td>Definition</td></tr><tr><td>01</td><td>[MU:EUL AMPOULE ESSENCE]</td><td>0.00</td><td>No irritation</td></tr></table>				No. <sup>1)</sup>	Designation	Skin irritation index	Definition	01	[MU:EUL AMPOULE ESSENCE]	0.00	No irritation
	No. <sup>1)</sup>	Designation	Skin irritation index	Definition								
	01	[MU:EUL AMPOULE ESSENCE]	0.00	No irritation								
<sup>1)</sup> Location of the patch application												
The [MU:EUL AMPOULE ESSENCE] from ALPCH Co., Ltd. was defined as non-irritating product for human skin primary irritation.												

## 1. Objective

This study was performed to evaluate the safety of the [MU:EUL AMPOULE ESSENCE] from ALPCH Co., Ltd.

## 2. Study period

From 7<sup>th</sup> September 2021 to 9<sup>th</sup> September 2021

## 3. Investigational product

### 1) Inform of the investigational product

Table 1. Inform of the investigational product

No. <sup>1)</sup>	Product code <sup>2)</sup>	Designation	Formula	Concentration
01	IP-2108-034	[MU:EUL AMPOULE ESSENCE]	White cream	As is

<sup>1)</sup> Location of the patch application

<sup>2)</sup> Identification code of the investigational product by Oracle Skin Clinical Trial Center Co., Ltd.

### 2) Maintenance and storing of the investigational product

Investigational product information was immediately recorded in the sample ledger after received. Investigational product will be stored for a month before gets discarded.

### 3) Safety of the investigational product

The sponsor has agreed to take responsibility for compensation of any adverse event caused by investigational product during the study period. However, medical expenses and hospitalization which are unrelated to this study were excluded from the agreement.



#### 4. Subjects

In this study, subjects were selected on the basis of inclusion and exclusion criteria and consisted of 31 subjects over the age 19 years old.

##### 1) Inclusion criteria

- Male and female adults over the age 19 years-old
- Subjects who have signed consent form voluntarily after being sufficiently informed regarding the objectives of study and all related contents
- Subjects who are healthy without acute and chronic diseases including skin disorders
- Subjects who can be observed and traced throughout the entire study period

##### 2) Exclusion criteria

- Subject who is pregnant or breast-feeding
- Subject who has psychiatric disease and infectious skin disease
- Subject who has chronic disease such as asthma, diabetes, high blood pressure, etc.
- Subject who has skin lesion on the test site such as moles, pimples, erythema, scalds (burns), hemotelangiosis, and scars
- Subject who has used skin ointment containing steroid on the test site for more than one month
- Subject who has sensitive and hypersensitive skin
- Subject who has irritation history or allergy to adhesive tape
- Subject who has been part of the same clinical trial within the past 3 months
- Subject who is on contraceptive, anti-histamine and anti-inflammatory prescriptions
- Subject who has cosmetics or sunlight allergies
- Employee in this clinical trial center
- Anyone who is considered non-qualified by the investigator

## 3) Number of subjects

This study was conducted in compliance with the "Regulations on Functional Cosmetic Examination [Annex 1] Toxicity Test Method Section 7 (1) Human patch test method" by the MFDS (Ministry of Food and Drug Safety). The results were calculated by obtaining the valid data from a minimum of 30 subjects.

## 4) Criteria for premature withdrawal and dropout from the study

The subjects who participating in this study can withdraw from the clinical trial any time, and the investigator can eliminate subjects from this test and exclude the data on the subject from the test result evaluation in the event of occurrence of one or more of the following reasons. When a subject is withdrawn, the investigator shall specify the corresponding reason and records other relevant matters to report to the principal investigator.

- (1) Voluntary withdrawal by the subject
- (2) Violation of the protocol
- (3) Occurrence of adverse event or seriously adverse event on the test site of a subject
- (4) Failure to follow up on the subject
- (5) Others

## 5) Maintenance of confidential information and duty of good faith

- (1) Confidentiality of personal information of subjects participating in the clinical trial will be maintained. However, the test data can be used for medical, academic research or marketing purposes within the scope of not disclosing the identity of the subject.
- (2) The subjects maintained confidentiality of information obtained through the clinical trial until the end of the test.
- (3) Subjects participating in the clinical trial filled out the documents related to the clinical trial sincerely and frankly.

## 5. Materials to conduct the study

- 1) IQ Ultra™ (Chemotechnique MB Diagnostics AB, Sweden)
- 2) Microman M100 (Gilson, France)
- 3) Micropore tape (3M/ Medical-Surgical Division)
- 4) Marking pen (Skin marker Slim, Sweden)

## 6. Methodology

- 1) Test method and application sites

Application site is located on the flat area of the subject's back but avoid the spine area and area where there is no skin discoloration or any lesion. Study was performed in more than 30 healthy male and female adult subjects with age over 19 years old. 20µl of the investigational product was applied on IQ Ultra and fixed to the application site for 24 hours with adhesive tape. The skin reaction was assessed at 30 minutes and 24 hours after patch removal.

- 2) Procedure

Table 2. Procedure

Actions	Day 1	Day 2	Day 3
Admission of the subjects by the investigator	O	-	-
Application of the investigational product and giving the subjects constraints of the study	O	-	-
Remove patch	-	O	-
Observation of test site after 30min of the patch removal	-	O	-
Observation of test site after 24hrs of the patch removal	-	-	O

- 3) Determination of irritation

The determination of skin irritation was assessed by the dermatologist at 30 minutes and 24 hours after removal of the skin patch based on Skin Irritation Evaluation Criteria. Skin reaction was assessed according to the Frosch & Kligman and CTFA guidelines, and skin irritation Index was calculated. The degree of skin irritation for test substances was categorized by referring to the skin irritation index applied with the Draize method (Table 3-4, Fig 1).

Table 3. Skin Irritation Evaluation Criteria

Mark	Score	Description
-	0	No reaction
+	1	Slight erythema, either spotty or diffuse
++	2	Moderate uniform erythema
+++	3	Intense erythema with edema
++++	4	Intense erythema with edema & vesicles

Fig 1. Skin Irritation Index Formula

Skin Irritation Index

$$= \frac{\left[ \left( \frac{\sum_{i=1}^n \text{Evaluation Value}}{n(\text{Number of Test Subjects})} \right) 30\text{min} + \left( \frac{\sum_{i=1}^n \text{Evaluation Value}}{n(\text{Number of Test Subjects})} \right) 24\text{hrs} \right]}{m(\text{Number of times evaluated})}$$

Table 4. Result Determination Table of Skin Patch Test

Primary Irritation Index	Irritation Evaluation
0.00 - 0.25	No irritation
0.26 - 1.00	Mild irritation
1.01 - 2.50	Medium irritation
2.51 - 4.00	Strong irritation

#### 4) Adverse Event

Researchers conducted visual assessment for adverse event in test area and checked for severity of symptoms at each visit. Subjects are also instructed to report immediately when they felt any abnormal symptoms during the test period, whether on the visit day or not. In the event that skin adverse events are reported, researchers notify the principal investigator immediately. The principal investigator confirms the adverse event, takes proper measures, and decides whether to continue participate in the clinical trial.

## 7. Results

### 1) Inform of the subjects


This study was initially conducted with 31 Korean male and female adults who met all the inclusion criteria, exclusion criteria. Since 0 subject have withdrawn during the study period, total 31 subjects included this result.

Average age of subjects is 30.4 years old, the oldest is 42 years old and the youngest is 21 years old (Table 5, Fig 2).

Table 5. Inform of the subjects

<b>Enrolled</b>		31
<b>Dropped</b>		0
<b>Completed</b>		31
<b>Gender</b>	<b>Female</b>	21
	<b>Male</b>	10
<b>Average age</b>		30.4

Fig 2. Distribution of Subjects gender and age



## 2) Results of skin irritation index and definition

Dermatologist performed a visual evaluation at 30 minutes and 24 hours after removal of the patch. As a result, the [MU:EUL AMPOULE ESSENCE] was defined as "non-irritating product" with "0.00" skin irritation index score (Table 6).

Table 6. Results of skin irritation index and definition

No. <sup>1)</sup>	Designation	30min <sup>†</sup>				24hrs <sup>‡</sup>				Skin irritation index	Definition
		1	2	3	4	1	2	3	4		
01	[MU:EUL AMPOULE ESSENCE]	-	-	-	-	-	-	-	-	0.00	No irritation

<sup>1)</sup>Location of the patch application

<sup>†</sup>30 min after removal of the patch

<sup>‡</sup>24 hours after removal of the patch

## 3) Adverse Event

As a result of the physical examination by the dermatologist, no specific skin adverse events were observed during the study period.

## 8. Conclusion

This study was performed to evaluate the safety of the [MU:EUL AMPOULE ESSENCE] from ALPCH Co., Ltd.

The study was performed in more than 30 healthy male and female adult subjects with age over 19 years old. Application site is located on the flat area of the subject's back but avoid the spine area and area where there is skin discoloration or any lesion. 20 $\mu$ l of the investigational product was applied on IQ Ultra and fixed to the application site for 24 hours with adhesive tape. The skin reaction was assessed at 30 minutes and 24 hours after patch removal.

**The [MU:EUL AMPOULE ESSENCE] from ALPCH Co., Ltd. was defined as non-irritating product for human skin primary irritation.**

## 9. Reference

- 1) Guidelines for test methods for demonstrating cosmetic mark advertising, Ministry of Food and Drug Safety. 2018.
- 2) Guidelines for cosmetic clinical and efficacy examination, Ministry of Food and Drug Safety. 2015.
- 3) Basketter DA, Chamnerlain M, Griffiths HA, Rowson M, Whittle E, York M. The classification of skin irritants by human patch test. Food Chem Toxicol. 1997;35(8): 845-52.
- 4) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1981:20005.
- 5) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1991:20036.
- 6) Devos SA, Van Der Valk PG. Epicutaneous patch testing. Eur J Dermatol. 2002;12(5): 506-13.
- 7) Draize J.H., Woodard G., Calvery H.O. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharm. Exp. Ther. 1994;82:377-390.
- 8) Draize J.H. Dermal Toxicity Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, Association of Food and Drug Officials of the United States, Austin, Tex, USA. 1959.
- 9) Electrical impedance applied to non-invasive detection of irritation in skin. Contact dermatitis. 1992;27:37-42.
- 10) Fischer T, Maibach H. Finn chamber patch test technique. Contact dermatitis. 1984; 11(3):137-140.
- 11) Frosch P. J. & Kligman A.M. The soap chamber; a new method for assessing the irritancy. J. Invest. Dermatol. 1979;40:11-14.



## Appendix 1. Inform of the subjects

Subject No.	Identification code*	Registration number*	Gender	Age
01	INJES01	00101	Female	31
02	HYLES02	00102	Male	38
03	YEKOS03	00103	Male	34
04	UKSHS04	00104	Male	28
05	TAKIS05	00105	Male	36
06	MIJES31	00131	Female	30
07	YOLIS34	00134	Female	24
08	JUCHS32	00132	Male	31
09	WOJES33	00133	Male	42
10	GUJES07	00107	Male	34
11	SELIS08	00108	Male	35
12	JUSOS09	00109	Female	28
13	INGWS10	00110	Female	34
14	GYBAS11	00111	Male	41
15	GELES12	00112	Male	42
16	JEOHS15	00115	Female	33
17	SOKIS16	00116	Female	28
18	RASOS17	00117	Female	28
19	SELES18	00118	Female	30
20	HYCHS19	00119	Female	23
21	SEYOS20	00120	Female	21
22	HYLES21	00121	Female	21
23	JULES22	00122	Female	28
24	EIKIS23	00123	Female	31
25	JUJIS24	00124	Female	24
26	JEKIS25	00125	Female	28
27	YOKIS26	00126	Female	23
28	JILES27	00127	Female	26
29	JIPAS28	00128	Female	22
30	SUKIS29	00129	Female	35
31	JUKIS30	00130	Female	32

\*Identification code and number by Oracle Skin Clinical Trial Center Co., Ltd.

## Appendix 2. Ingredients of the investigational product

### [MU:EUL AMPOULE ESSENCE]

Water (Glacier Water), Water, Propanediol, Glycerin, 1,2-Hexanediol, Niacinamide, Butyrospermum Parkii (Shea) Butter, Caprylic/Capric Triglyceride, Cetyl Ethylhexanoate, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Butylene Glycol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Panthenol, Tromethamine, Ethylhexylglycerin, Lactobacillus Ferment, Lactobacillus Ferment Lysate, Lactobacillus Ferment Filtrate, Sorbitan Isostearate, Adenosine, Centella Asiatica Extract, Glyceryl Glucoside, Origanum Vulgare Leaf Extract, Chamaecyparis Obtusa Leaf Extract, Salix Alba (Willow) Bark Extract, Hydroxystearic Acid, Lactobacillus/Soybean Ferment Extract, Portulaca Oleracea Extract, Cinnamomum Cassia Bark Extract, Scutellaria Baicalensis Root Extract, Octyldodecanol, Sodium Hyaluronate, Ulmus Davidiana Root Extract, Aloe Barbadensis Leaf Extract, Laminaria Japonica Extract, Dioscorea Japonica Root Extract, Viola Mandshurica Flower Extract, Benzyl Glycol, Cymbopogon Schoenanthus Leaf/Stem Extract, Hydrogenated Lecithin, Hydrolyzed Glycosaminoglycans, Ceramide NP, Hydrogenated Phosphatidylcholine, Pueraria Lobata Root Extract, Oenothera Biennis (Evening Primrose) Flower Extract, Pinus Palustris Leaf Extract, Sodium Hyaluronate Crosspolymer, Sucrose Stearate, Hydrolyzed Hyaluronic Acid, Asiaticoside, Madecassic Acid, Asiatic Acid, Caprylyl Glycol, Cholesterol, Hydroxypropyltrimonium Hyaluronate, Hyaluronic Acid, Potassium Hyaluronate, Hydrolyzed Sodium Hyaluronate, Madecassoside, Sodium Acetylated Hyaluronate, Disodium EDTA

### Appendix 3. Result data

Subject No.	[MU:EUL AMPOULE ESSENCE]		Distilled water		Blank	
	30min <sup>†</sup>	24hrs <sup>‡</sup>	30min <sup>†</sup>	24hrs <sup>‡</sup>	30min <sup>†</sup>	24hrs <sup>‡</sup>
01	0	0	0	0	0	0
02	0	0	0	0	0	0
03	0	0	0	0	0	0
04	0	0	0	0	0	0
05	0	0	0	0	0	0
06	0	0	0	0	0	0
07	0	0	0	0	0	0
08	0	0	0	0	0	0
09	0	0	0	0	0	0
10	0	0	0	0	0	0
11	0	0	0	0	0	0
12	0	0	0	0	0	0
13	0	0	0	0	0	0
14	0	0	0	0	0	0
15	0	0	0	0	0	0
16	0	0	0	0	0	0
17	0	0	0	0	0	0
18	0	0	0	0	0	0
19	0	0	0	0	0	0
20	0	0	0	0	0	0
21	0	0	0	0	0	0
22	0	0	0	0	0	0
23	0	0	0	0	0	0
24	0	0	0	0	0	0
25	0	0	0	0	0	0
26	0	0	0	0	0	0
27	0	0	0	0	0	0
28	0	0	0	0	0	0
29	0	0	0	0	0	0
30	0	0	0	0	0	0
31	0	0	0	0	0	0

<sup>†</sup>30 min after removal of the patch

<sup>‡</sup>24 hours after removal of the patch

0: No reaction, 1: Slight erythema, either spotty or diffuse, 2: Moderate uniform erythema,

3: Intense erythema with edema, 4: Intense erythema with edema &amp; vesicles

## Facilities and faculty involved in the study

■ Institution			
<b>Name</b>	Oracle Skin Clinical Trial Center Co., Ltd.		
<b>Address</b>	4F, Hanil Building, Seolleung-ro, Gangnam-gu, Seoul, Republic of Korea		
<b>President</b>	Youngwoo Ro		
<b>Principal Investigator</b>	Youngwoo Ro / Dermatologist		
<b>Tel.</b>	+82 10-3689-3340	<b>Fax</b>	+82 2-516-8966
<b>e-mail</b>	oracleclinicaltrials@gmail.com		

■ Purpose of establishment of Institute
<p>This institution was established to evaluate the safety, effectiveness, and functionality of the investigational products by performing clinical study, providing results of related tests as well as technical information.</p>

■ Clinical study items
<div> <div> Cosmetics safety evaluation and research  Cosmetics efficacy evaluation and research  Skin related product evaluation and research </div> <div> Functional cosmetics evaluation and research  Quasi-drugs evaluation and research  Functional food evaluation and research </div> </div>

## Researchers CV

### ■ President / Principal Investigator

Youngwoo Ro / CEO, Dermatologist

Education	1987.03 - 1993.02	Chungnam National University College of Medicine, Bachelor of Medicine
	1994.03 - 1995.02	Chungnam National University College of Medicine, Graduate School, Master's Degree
Career	1993.03 - 1994.02	Chungnam National University Hospital, Intern
	1994.03 - 1998.02	Chungnam National University Hospital, Department of Dermatology, Resident
	1998.03 - 1999.02	Korea Army, Surgeon
	1999.03 - 2001.05	Korea Army Gwangju Hospital, Surgeon
	2001.05 - 2004.07	Ro Young-Woo Dermatology, Director
	2004.08 - Present	Oracle Dermatology, Director
	2021.07 - Present	Oracle Skin Clinical Trial Center, CEO

### ■ Quality Assurance

Hyewon Shin / Dermatologist

Education	2001.03 - 2005.02	Hanyang University College of Medicine, Bachelor of Medicine
	2006.03 - 2008.02	Hanyang University College of Medicine, Graduate School, Master's Degree
Career	1999.03 - 2001.02	Hanyang University College of Medicine
	2001.03 - 2005.02	Hanyang University College of Medicine, Department of Medicine
	2005.03 - 2006.02	Hanyang University Medical Center Internship Completion
	2006.03 - 2010.02	Hanyang University Medical Center, Completion of Department of Dermatology
	2010.02	Acquired license for dermatology
	2010.03 - 2014.03	Oracle Dermatology Apgujeong Branch
	2014.04 - 2015.09	Beautiful Dermatology Clinic
	2015.09 - Present	Cheongdam Oracle Dermatology, Director
	2021.07 - Present	Oracle Skin Clinical Trial Center, Quality Assurance Officer

■ Subinvestigator

Yunhee Hwang / Department manager

Education	2001.03 - 2008.02	Graduated from Department of Biotechnology, Dongguk University, Bachelor of Science
	2008.03 - 2010.02	Completed biochemistry course at Dongguk University Graduate School
Career	2010.12 - 2014.09	Senior Researcher of Efficacy Safety Research Team, IEC Korea Co., Ltd.
	2015.02 - 2015.07	Senior Researcher of Central Research Institute, P&K Skin Clinical Research Center
	2016.03 - 2018.04	Senior Researcher of Skin Biotechnology Center Clinical Research Institute, Kyunghee University, Team Leader
	2018.07 - 2019.10	Senior Researcher of Clinical Center, 3CR Co., Ltd., Team Leader
	2020.03 - 2021.03	Principal Researcher of Clinical Trial Division, Human Skin Clinical Trial Center, Division director
	2021.07 - Present	Oracle Skin Clinical Trial Center, Department manager

## List of scientific publications

No.	Journal
1	Young Woo Ro, Kyung Hoon Kim, Ki Beom Suhr, Jang Kyu Park. Two Cases of Clear Cell Hidradenoma. Korean Journal of Dermatology1996;34(2):300-303.
2	Young Woo Ro, Woo Jae Lee, Ki Beom Suhr, Jeong Hoon Lee, Jang Kyu Park. A Case of Kerion Celsi Caused by T. verrucosum in Chungcheong Province. Korean Journal of Dermatology1997;35(1):187-190.
3	Tae Won Kim, Woong Jae Lee, Jeung Hoon Lee, Jang Kyu Park. Effects of Autografting Using the Suction Blistered Epidermis Technique in the Treatment of Vitiligo. Korean Journal of Dermatology1998;36(1):103-106.
4	Youn Soo Kim, Tae Won Kim, Woong Jae Lee, Ki Beom Suhr, Jeung Hoon Lee. Minimal Phototoxic Dose for a Vitiliginous Skin Lesion. Korean Journal of Dermatology1998;36(2):241-245.
5	Young Woo Ro, Tae Won Kim, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 48 <sup>th</sup> Spring Meeting: Clinical Case Report; Metabolic disease: 2 cases of Nevus mucinosus occurring in adolescence. 1996;48(1):55-55. [Abstracts]
6	Young Woo Ro, Tae Won Kim, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 48 <sup>th</sup> Spring Meeting: Clinical Case Report; Metabolic disease: 2 cases of Nevus mucinosus occurring in adolescence. 1996;48(1):55-55. [Abstracts]
7	Youn Soo Kim, Young Woo Ro, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Spring Meeting: Vitiligo Symposium; Presentation: A study on the response of PUVA treatment in vitiligo patients. 1997;49(1):31-31. [Abstracts]
8	Tae Won Kim, Young Woo Ro, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Spring Meeting: Clinical Case Report; Infectious disease (1): 2 cases of atypical mycobacteriosis presumed to be infected in a bathroom. 1997;49(1):60-60. [Abstracts]
9	Nam Jang, Kwang Sung Choi, Tae Hyeon Park, Ki Soon Nam, Jeong Yeol Lee, Sung Kyu Yang, Sang Woong Yoon, Jong Gu Kim, Young Woo Ro, Il Moon Song, Gye Young Son, Jae Seok Yang, Dong Jun Kim, Sam Hyeong Kim. Korean Dermatological Association The 49 <sup>th</sup> Spring Meeting: Treatment Symposium (3); Prevalence of PPNG in Seoul (1996). 1997;49(1):75-75. [Abstracts]
10	Woong Jae Lee, Young Woo Ro, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Autumn Meeting: Skin tumor (1): A case of malignant simple sweat acanthoma. 1997;49(2):76-76. [Abstracts]

---

11	Youn Soo Kim, Young Woo Ro, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Autumn Meeting: Other diseases: A case of Michelin Thai baby syndrome. 1997;49(2):79-79. [Abstracts]
12	Jeung Hoon Lee, Youn Soo Kim, Woong Jae Lee, Young Woo Ro, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Autumn Meeting: General Poster; Inhibition of Epidermal Transglutaminase Expression. 1997;49(2):81-81. [Abstracts]
13	Youn Soo Kim, Young Woo Ro, Ki Beom Suhr, Jeung Hoon Lee, Jang Kyu Park. Korean Dermatological Association The 49 <sup>th</sup> Autumn Meeting: General Poster; A case of lightning burns. 1997;49(2):119-119. [Abstracts]

---

